Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Quadrise

    MCap

    GBP28m

    Last close

    GBP0.02

    ▲ 0.41 (26.62%)

    Substrate AI

    MCap

    EUR12m

    Last close

    EUR0.13

    ▲ 0.02 (18.18%)

    Games Workshop Group

    MCap

    GBP3,860m

    Last close

    GBP137.30

    ▲ 2,020.00 (17.25%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Abliva (OMX: ABLI)

Last close As at 22/11/2024

0.17

▲ −0.01 (−5.56%)

Market capitalisation

SEK195m

NeuroVive Pharmaceutical is a Swedish biopharmaceutical company with deep expertise in mitochondrial medicine. It has a diversified portfolio in terms of indications and employs a dual strategy: it develops a core portfolio of assets for orphan diseases and seeks to out-license proprietary products for non-orphan indications. NeuroSTAT (neurotrauma, Phase IIb ready) and KL1333 (genetic mitochondrial diseases) are the most advanced assets.

Latest Insights

View More

Healthcare | Update

Abliva — IND approved by the FDA, preparing for Ph II/III

Healthcare | Update

Abliva — KL1333 ready for pivotal Phase II/III trial

Healthcare | Update

Abliva — New strategic investor on board and CMD

Healthcare | Update

NeuroVive Pharmaceutical — Rights issue and focus on core assets
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (SEKm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (3.4) (11.9) (72.7)
Relative (0.9) (20.7) (63.8)
52 week high/low SEK0.6/SEK0.2

Financials

Edison Investment Research is terminating coverage on Abliva (ABLI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (fd) (öre) P/E (x) P/CF (x)
2020A 1.9 (55.0) (57.4) (23.00) N/A N/A
2021A 0.2 (117.9) (120.4) (34.44) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Research

Update

Healthcare

Abliva — KL1333 ready for pivotal Phase II/III trial

Update

Healthcare

Abliva — New strategic investor on board and CMD

Healthcare

Update

Abliva — IND approved by the FDA, preparing for Ph II/III
View All

Thematics

thematic

Healthcare

Healthcare-focused trusts: A sector on the mend

thematic

Healthcare

Outlook for 2024: Life sciences – where has the conviction gone?

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare
volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 
View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free